Is Protagonist Therapeutics Inc. (PTGX) Holding Up Well Over a Long-Time Horizon?

Protagonist Therapeutics Inc. [PTGX] stock prices are up 0.96% to $25.36 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PTGX shares have gain 1.28% over the last week, with a monthly amount glided 9.03%, and seem to be holding up well over a long-time horizon.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


On 12, May 2023, Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113. In a post published today on Yahoo Finance, Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases.

From an analyst’s perspective:

The stock price of Protagonist Therapeutics Inc. [PTGX] has been fluctuating between $6.91 and $26.87 over the past year. Currently, Wall Street analysts expect the stock to reach $36.33 within the next 12 months. Protagonist Therapeutics Inc. [NASDAQ: PTGX] shares were valued at $25.36 at the most recent close of the market. An investor can expect a potential return of 43.26% based on the average PTGX price forecast.

Analyzing the PTGX fundamentals

A company’s income per employee is -$1,213,267 while it generates $253,152 in revenue per employee. Gross Margin for this corporation currently stands at +96.12% with Operating Margin at -494.24%, Pretax Margin comes in at -479.26%, and Net Margin reading is -479.26%. To continue investigating profitability, this company’s Return on Assets is posted at -42.78, Equity is -49.41, Total Capital is -50.03, and Invested Capital is -48.96. Taking a look at the Principal structure of this organization reveals enduring liabilities to the total capital at 1.67 and enduring liabilities to the whole assets at 1.47.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.95 points at the first support level, and at 24.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.15, and for the 2nd resistance point, it is at 26.95.

Protagonist Therapeutics Inc. [PTGX] reported earnings per share of -$0.67 for its fiscal quarter that ended on 3/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.73/share, meaning a difference of $0.06 and a surprise factor of 8.20%. By comparison, the stated earnings for the previous quarter ended on 12/30/2022 were -$0.69 per share as compared to estimates of -$0.64 per share, a difference of -$0.05 representing a surprise of -7.80%.

Ratios To Look Out For

It’s worth pointing out that Protagonist Therapeutics Inc. [NASDAQ:PTGX]’s Current Ratio is 10.10. As well, the Quick Ratio is 7.80, while the Cash Ratio is 7.61. Considering the valuation of this stock, the price to sales ratio is 20.13, the price to book ratio is 2.50.

Transactions by insiders

Insider trading has also been a hot topic recently, with 1 insiders purchasing 6,196 shares and 1 selling 1,189 shares in the past 3 months.